Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and potassium thiocyanate. DHA and EPA are omega-3 polyunsaturated fatty acids commonly found in fish oil, known for their lipid-lowering, anti-inflammatory, and cardioprotective effects. Potassium thiocyanate is a salt that has been historically used as an antihypertensive agent and investigated for its potential to modulate vascular function. In pilot clinical research, this combination was studied in children with sickle cell anemia to assess its effect on cerebral artery blood velocity; results suggested it may help normalize or prevent progression of abnormal blood flow velocities associated with increased stroke risk in this population[1]. The mechanism likely involves the anti-inflammatory properties of omega-3 fatty acids combined with the vasodilatory or modulatory effects of potassium thiocyanate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docosahexaenoic acid + eicosapentaenoic acid + potassium thiocyanate.